Compound as 20-HETE generation inhibitor

WO2026037255A1PCT designated stage Publication Date: 2026-02-19HANGZHOU INNOGATE PHARMA CO LTD +1

-1 Cites -1 Cited by

Patent Information

Application Number: PCT/CN2025/113947
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-08-10
Filing Date: 2025-08-11
Publication Date: 2026-02-19

Application Information

Patent Timeline

10 Aug 2024

Priority

11 Aug 2025

Application

PCT/CN2025/113947

19 Feb 2026

Publication

WO2026037255A1

IPC: C07D401/14; C07D403/10; C07D413/14; C07D471/04; A61K31/5377; A61K31/4545; A61P3/04; A61P3/10

CPC: A61K31/4545; A61K31/5377; A61P3/04; A61P3/10; C07D401/14; C07D403/10; C07D413/14; C07D471/04

Inventors: ZHANG, HANCHENG; CAI, CONGCONG

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Smart Images

Figure CN2025113947_19022026_PF_FP_ABST

Patent Text Reader

Abstract

The present invention provides a class of compounds. Particularly, the present invention provides a compound having a structure represented by the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate or solvate thereof. The compound can effectively inhibit the generation of 20-HETE, and is used for treating or preventing diseases or disorders related to 20-HETE.

Need to check novelty before this filing date? Find Prior Art